prof. Hannelore Denys

Journal Article
A1
open access

Breast cancer Intraoperative Margin Assessment using specimen PET-CT (BIMAP)

Anne-Sofie De Crem, Philippe Tummers (UGent) , Herman Depypere (UGent) , Geert Braems (UGent) , Rawand Salihi (UGent) , Glenn Vergauwen (UGent) , Giovanni Cisternino, Koen Van de Vijver (UGent) , Pieter De Visschere (UGent) , Kathia De Man (UGent) , et al.

(2025) NPJ BREAST CANCER. 11(1).

Add to list

Journal Article
A1
open access

Safety and efficacy of the therapeutic DNA-based vaccine VB10.16 in combination with atezolizumab in persistent, recurrent or metastatic HPV16-positive cervical cancer : a multicenter, single-arm phase 2a study

Peter Hillemanns, Michal Zikan, Frédéric Forget, Hannelore Denys (UGent) , Jean-Francois Baurain, Lukas Rob, Linn Woelber, Pawel Blecharz, Mariusz Bidzinski, Josef Chovanec, et al.

(2025) JOURNAL FOR IMMUNOTHERAPY OF CANCER. 13(1).

Add to list

Journal Article
A1
open access

Tumor Treating Fields therapy in platinum-resistant ovarian cancer : results of the ENGOT-ov50/GOG-3029/INNOVATE-3 pivotal phase 3 randomized study

Ignace Vergote, Larry J. Copeland, Toon Van Gorp, Annouschka Laenen, Giovanni Scambia, Premal H. Thaker, David Cibula, Nicoletta Colombo, Jayanthi Lea, Antonio Gonzalez-Martin, et al.

(2025) EUROPEAN JOURNAL OF CANCER. 219.

Add to list

Journal Article
A1
open access

Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancer

Whitney S Graybill, Ignace Vergote, Bhavana Pothuri, Maarit Anttila, David M O'Malley, Domenica Lorusso, Ashley F Haggerty, Michel Fabbro, John K Chan, Florian Heitz, et al.

(2025) JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH. 14(1).

Add to list

Journal Article
A2
open access

Management of severe capecitabine-induced corneal toxicity

Mathieu Heyvaert, Hannelore Denys (UGent) , Jo Van Dorpe (UGent) and Dimitri Roels (UGent)

(2024) AMERICAN JOURNAL OF OPHTHALMOLOGY CASE REPORTS. 36.

Add to list

Journal Article
A1
open access

Niraparib population pharmacokinetics and exposure-response relationships in patients with newly diagnosed advanced ovarian cancer

Bradley J. Monk, Ignacio Romero, Whitney Graybill, Cristina Churruca, David M. O'Malley, Anja Ør Knudsen, Oi Wah Stephanie Yap, Jean-François Baurain, Peter G. Rose, Hannelore Denys (UGent) , et al.

(2024) CLINICAL THERAPEUTICS. 46(8). p.612-621

Add to list

Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2) : a multi-dose, open-label, randomised, phase 2 trial

Mafalda Oliveira, Denys Pominchuk, Zbigniew Nowecki, Erika Hamilton, Yaroslav Kulyaba, Timur Andabekov, Yevhen Hotko, Tamar Melkadze, Gia Nemsadze, Patrick Neven, et al.

(2024) LANCET ONCOLOGY. 25(11). p.1424-1439

Add to list

GRACE-trial : a randomized active-controlled trial for vulvovaginal atrophy in breast cancer patients on endocrine therapy

Glenn Vergauwen (UGent) , Piet Cools (UGent) , Hannelore Denys (UGent) , Tom Fiers (UGent) , Koen Van de Vijver (UGent) , Liv Veldeman (UGent) and Hans Verstraelen (UGent)

(2024) CANCER RESEARCH. In Cancer Research 84(9, Supplement S).

Add to list

Miscellaneous
open access

Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma : results of the phase II PRIMMO study (vol 72, pg 475, 2022)

Emiel De Jaeghere (UGent) , Sandra Tuyaerts, An M. T. Van Nufel, Ann Belmans, Kris Bogaerts, Regina Baiden-Amissah, Lien Lippens (UGent) , Peter Vuylsteke, Stéphanie Henry, Xuan Bich Trinh, et al.

(2024) CANCER IMMUNOLOGY IMMUNOTHERAPY. 74(1).

Add to list

Journal Article
A1
open access

Pelophen B is a non-taxoid binding microtubule-stabilizing agent with promising preclinical anticancer properties

Stephanie Vermeulen (UGent) , Sam Ernst (UGent) , Eva Blondeel (UGent) , Zihan Xia (UGent) , Pekka Rappu, Jyrki Heino, Sandor Dedeyne (UGent) , Hannelore Denys (UGent) , Gwen Sys (UGent) , Stefanie Gijsels (UGent) , et al.

(2024) SCIENTIFIC REPORTS. 14(1).

Academic Bibliography

prof. Hannelore Denys

Breast cancer Intraoperative Margin Assessment using specimen PET-CT (BIMAP)

Safety and efficacy of the therapeutic DNA-based vaccine VB10.16 in combination with atezolizumab in persistent, recurrent or metastatic HPV16-positive cervical cancer : a multicenter, single-arm phase 2a study

Tumor Treating Fields therapy in platinum-resistant ovarian cancer : results of the ENGOT-ov50/GOG-3029/INNOVATE-3 pivotal phase 3 randomized study

Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancer

Management of severe capecitabine-induced corneal toxicity

Niraparib population pharmacokinetics and exposure-response relationships in patients with newly diagnosed advanced ovarian cancer

Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2) : a multi-dose, open-label, randomised, phase 2 trial

GRACE-trial : a randomized active-controlled trial for vulvovaginal atrophy in breast cancer patients on endocrine therapy

Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma : results of the phase II PRIMMO study (vol 72, pg 475, 2022)

Pelophen B is a non-taxoid binding microtubule-stabilizing agent with promising preclinical anticancer properties

Contents

Support

Contact